Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.
A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.
GLP-1 weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, ...
The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...
In this cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with reduced risk of developing ...
Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study ...
Patients with various combinations of CKM comorbidities who receive GLP-1RAs have decreased risk for HF hospitalization and CV death.
GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.
A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial ...
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three ...
Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health risks in people with type 2 diabetes than other types of glucose-lowering ...
Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. The biopharmaceutical company said Tuesday it will not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results